title: Characterization of Salvia miltiorrhiza ethanol extract as an anti-osteoporotic agent.
abstract: BACKGROUND
  Salvia miltiorrhiza (SM) has long been used as a traditional oriental medicine for cardiovascular disease. Accumulating evidence also indicates that SM has anti-osteoporotic effects. This study was conducted to examine the SM-induced anti-osteoporotic effect and its possible mechanisms with various doses of SM.
  
  
  METHODS
  We studied Sprague-Dawley female rats aged 12 weeks, divided into six groups: sham-operated control (SHAM), OVX rats supplemented with SM (1, 3, 10 and 30 mg/kg) orally for 8 weeks. At the end of the experiment, blood samples were collected and biochemistry analysis was performed. Specimens from both tibia and liver were processed for light microscopic examination. DEXA and μ-CT analyses of the tibia were also performed.
  
  
  RESULTS
  SM treatment significantly ameliorated the decrease in BMD and trabecular bone mass according to DEXA and trabecular bone architecture analysis of trabecular bone structural parameters by μ-CT scanning. In serum biochemical analysis, SM decreased the released TRAP-5b, an osteoclast activation marker and oxidative stress parameters including MDA and NO induced by OVX.
  
  
  CONCLUSIONS
  The preventive effect of SM was presumably due to its anti-oxidative stress partly via modulation of osteoclast maturation and number. In current study, SM appears to be a promising osteoporosis therapeutic natural product.
authors: Department of Pharmacology, Chonbuk National University, Jeonju, Chonbuk, South Korea.
authors: Yan
authors: Y
authors: Cui
authors: Bidur
authors: B
authors: Bhandary
authors: Anu
authors: A
authors: Marahatta
authors: Geum-Hwa
authors: GH
authors: Lee
authors: Bo
authors: B
authors: Li
authors: Do-Sung
authors: DS
authors: Kim
authors: Soo-Wan
authors: SW
authors: Chae
authors: Hyung-Ryong
authors: HR
authors: Kim
authors: Han-Jung
authors: HJ
authors: Chae
mesh_terms: D000818:Animals; D000975:Antioxidants / Q000494:pharmacology / Q000627:therapeutic use; D015519:Bone Density / Q000187:drug effects*; D050071:Bone Density Conservation Agents / Q000494:pharmacology / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008315:Malondialdehyde / Q000097:blood; D009569:Nitric Oxide / Q000097:blood; D010010:Osteoclasts / Q000187:drug effects; D015663:Osteoporosis, Postmenopausal / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000517:prevention & control; D010052:Ovariectomy; D018384:Oxidative Stress / Q000187:drug effects*; D008517:Phytotherapy; D010936:Plant Extracts / Q000494:pharmacology / Q000627:therapeutic use*; D011859:Radiography; D051381:Rats; D017207:Rats, Sprague-Dawley; D027561:Salvia miltiorrhiza; D013977:Tibia / Q000033:anatomy & histology / Q000187:drug effects / Q000378:metabolism
chemical_list: D000975:Antioxidants; D050071:Bone Density Conservation Agents; D010936:Plant Extracts; D009569:Nitric Oxide; D008315:Malondialdehyde